Network pharmacology analysis clarified a potential mechanism underlying the role of SJZD in the CRC TME and indicated that HSPB1, SPP1, IGFBP2 and TGFB1 could be potential therapeutic targets in the CRC TME. Here, SPP1 is linked to colorectal carcinoma.